AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca has recently completed a Phase IV clinical study titled ‘Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone.’ The study aimed to assess the efficacy and safety of SZC in managing high potassium levels in patients with symptomatic heart failure and reduced ejection fraction (HFrEF) who are on spironolactone. This study is significant as it addresses the challenge of maintaining normal potassium levels in this patient population, potentially improving their treatment outcomes.
The intervention being tested is Sodium Zirconium Cyclosilicate (SZC), a drug designed to manage hyperkalemia by maintaining potassium levels within the normal range, alongside a placebo and the background use of spironolactone.
The study was interventional, with a randomized, double-blind, placebo-controlled, parallel-group design. Participants were randomly allocated to receive either SZC or a placebo, with both participants and investigators blinded to the treatment. The primary purpose was treatment-focused, aiming to evaluate the effectiveness of SZC in maintaining normal potassium levels.
The study began on March 8, 2021, with primary completion and results first submitted in April 2025. The last update was submitted in July 2025. These dates are crucial as they indicate the study’s timeline and the availability of results for analysis.
The completion of this study could have positive market implications for AstraZeneca, potentially boosting investor confidence and stock performance if the results demonstrate significant benefits of SZC over the placebo. This could position AstraZeneca favorably against competitors in the cardiovascular treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.